Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Merck partners with University of California, San Diego (UCSD) to fight Neglected Tropical Diseases
- Details
- Category: Merck Group
![Merck Merck](/images/logo/merckgroup.png)
Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting
- Details
- Category: Eli Lilly and Company
![Eli Lilly and Company Eli Lilly and Company](/images/logo/lilly.png)
Novartis expands development programs for NASH through clinical collaboration with Allergan
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds
- Details
- Category: Bristol-Myers Squibb
![Bristol-Myers Squibb Bristol-Myers Squibb](/images/logo/bms.png)
PatientsLikeMe and Shire Pharmaceuticals collaborate to study rare genetic diseases
- Details
- Category: Shire
![Shire Shire](/images/logo/shire.png)
Health risk assessments shed light on early predictors of depression
- Details
- Category: Johnson & Johnson
![Johnson & Johnson Johnson & Johnson](/images/logo/jnj.png)
More Pharma News ...
- Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer
- Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
- First collaborative definition of patient centricity
- Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
- Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
- The first overall survival data from the Phase 3 CheckMate -067 clinical trial
- Tagrisso (osimertinib) receives US FDA full approval